SOHO 2021 | Latest updates from the Phase I/II BRUIN study
Catherine C. Coombs, MD, The University of North Carolina Cancer Center, Chapel Hill, NC, shares the latest data from the Phase I/II BRUIN trial (NCT03740529) investigating the Bruton’s tyrosine kinase inhibitor (BTKi) pirtobrutinib in previously treated chronic lymphocytic leukaemia (CLL), small lymphocytic lymphoma (SLL) and non-Hodgkin lymphoma (NHL). Approximately 170 patients were studied for safety and efficacy. Dr Coombs reports an overall response rate of 63%, which was found to increase in patients who continued on the treatment for longer, and an over 80% response rate in patients who received pirtobrutinib for 10 months or longer. It was also found that response did not differ among patients who had prior BTKi exposure and was not dependent on the reason for previous BTKi discontinuation. This interview took place during the ninth annual meeting of the Society of Hematologic Oncology (SOHO 2021) congress.
Disclosures
Catherine C. Coombs, MD, has received honoraria or participated in consultancy work for AbbVie, Genentech, AstraZeneca, LOXO, Novartis and MEI Pharma; and has received institutional funding from AbbVie, LOXO, Incyte and h3 biomedicine.
